YES, Your Nostradamus of WallSreet Biotech is Here. Look people, let's not make this a habit though.
So you all want my thoughts on this and why I started pumping like a madman, as some have said.
Here is the deal. 1. Neopulse (head and neck indications) has been submitted to the EEU for registration. It's under review. I did my DD and saw the filing. Anyone here read French? That was done three months ago, so I believe the review may be coming to a close for a blind side decision soon.
Deal number 2. Immunopulse for melanoma, Stage 2 or possibly 3. Look, the company needs a partner to garner enough cash to pay for the all expensive Phase 3. I believe the deal is close to done, and I believe once they file with the SEC it goes public fast. My guestimate is end of September or beginning of October, and I have an idea whom it is. Actually it's a toss-up between two corporations. I see this is as another catalyst. One clue is the recent hire as the connection.
Deal number 3. I believe the FDA may also allow a fast track status for neopulse if the EEU approves it. I think it is almost a sure thing, the timeline on this I am not sure of. I suppose it will depend on how fast their regulatory consultant firm proposes that they file with the FDA but I believe it will happen by March 2015.
So, there you have it. My take on solid PPS movers. There are also other outliers which the company has not disclosed and I believe more equity is on the way with added product use indications, perhaps other therapies etc....
all in all, this appears to be the turning point. since it was obvious that they got the attention of ASCO well enough and Wallstreet and the big pharmas are taking electroporation more seriously each passing day. See the Bloomberg write-up on insider buying for INO this past week. It made the top ten and front page. And whom is INo associated with? That's right....So how long before you see this copr sell out? Could be sooner than later as in within a year or two and it will not be cheap. Not if they continue to meet the FDA regulatory therapy benefit endpoints and INO continuing to make skeptics look foolish.
I see $$$ on the way this fall and I always like the retail bios more in the Fall anyway due to the Holding corp sell off for filing the 2014 tax loss. You bet ONCS will see a spike. MM's, trading clubs and large private investors are no fools. IMHO
-M-
